Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Hypertension and Cardiovascular Disease: Clinical Updates and Perspectives
share announcement

Hypertension and Cardiovascular Disease: Clinical Updates and Perspectives

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: 30 April 2025 | Viewed by 2192

Special Issue Editors

Dr. Valeria Visco

E-Mail Website
Guest Editor
Department of Medicine and Surgery, University of Salerno, 84081 Baronissi, Italy
Interests: heart failure; arterial hypertension; telemonitoring; cardiovascular diseases; echocardiography
Special Issues, Collections and Topics in MDPI journals
Dr. Michele Ciccarelli

E-Mail Website
Guest Editor
Department of Medicine and Surgery, University of Salerno, 84081 Baronissi, Italy
Interests: molecular and clinical cardiology; new approaches for treatment of cardiovascular diseases
Special Issues, Collections and Topics in MDPI journals
Dr. Costantino Mancusi

E-Mail Website
Guest Editor
Department of Advanced Biomedical Sciences, Federico II University of Naples, Via S. Pansini 5, 80131 Napoli, Italy
Interests: cardiovascular disease; hypertension; heart failure
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue aims to provide a comprehensive overview of the latest advancements, research findings, and clinical perspectives in the field. Hypertension and cardiovascular disease continue to be significant health concerns worldwide, necessitating continuous updates and insights into their diagnosis, management, and prevention.

This Special Issue invites original research articles, review papers, and case studies that address various aspects of hypertension and cardiovascular disease within the clinical scope. We welcome submissions focusing on emerging diagnostic techniques, novel treatment approaches, risk assessment models, and preventive strategies. Additionally, articles exploring the impact of lifestyle modifications, pharmacological interventions, and personalized medicine in managing hypertension and cardiovascular disease are encouraged.

Authors are encouraged to contribute articles that shed light on the pathophysiology, epidemiology, and genetic factors associated with these conditions. Furthermore, we encourage submissions that explore the intersection between hypertension, cardiovascular disease, and other comorbidities such as diabetes, obesity, and renal disorders.

By bringing together diverse perspectives and up-to-date research, this Special Issue aims to enhance our understanding of hypertension and cardiovascular disease and contribute to improved patient care and outcomes.

Dr. Valeria Visco
Dr. Michele Ciccarelli
Dr. Costantino Mancusi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hypertension management
  • cardiovascular risk assessment
  • novel antihypertensive therapies
  • hypertension in pregnancy
  • hypertensive emergencies
  • cardiovascular disease prevention
  • pharmacological interventions for cardiovascular disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 289 KiB  
Article
Protective Influence of SGLT-2 Inhibitors Against Heart Failure in Type 2 Diabetes Mellitus Through Longitudinal Clinical Database Analysis
by Attila Csaba Nagy, Ágnes Tóth, Natália Bak, Battamir Ulambayar, Amr Sayed Ghanem and Ferenc Sztanek
J. Clin. Med. 2024, 13(23), 7093; https://doi.org/10.3390/jcm13237093 (registering DOI) - 24 Nov 2024
Abstract
Background: Sodium–glucose co-transporter 2 (SGLT-2) inhibitors, initially designed for type 2 diabetes, promote glucose excretion and lower blood glucose. Newer analogs like empagliflozin and dapagliflozin improve cardiovascular outcomes through mechanisms other than glycemic control, including blood pressure reduction and anti-inflammatory effects. Given [...] Read more.
Background: Sodium–glucose co-transporter 2 (SGLT-2) inhibitors, initially designed for type 2 diabetes, promote glucose excretion and lower blood glucose. Newer analogs like empagliflozin and dapagliflozin improve cardiovascular outcomes through mechanisms other than glycemic control, including blood pressure reduction and anti-inflammatory effects. Given the high cardiovascular risk present in diabetes, our study aims to emphasize the cardioprotective benefits of SGLT-2 inhibitors as a preventive therapy for heart failure (HF) in high-risk T2DM patients. Methods: Using data from 2542 patients identified by the ICD-10 E11 code from 2016 to 2020, this longitudinal study excluded those with E10 codes or those undergoing insulin treatment to focus on non-insulin-dependent T2DM. a multiple logistic regression model assessed HF incidence while adjusting for demographics and HbA1c. Results: SGLT-2 inhibitor use significantly lowered the odds of heart failure events (OR = 0.55, 95% CI: 0.31–0.99, p = 0.046), with a significant difference by gender (OR = 0.45, 95% CI: 0.28–0.71, p = 0.001) and eGFR (OR = 0.98, 95% CI: 0.97–0.99, p = 0.004). Conclusions: The real-world data highlight SGLT-2 inhibitors as promising for HF prevention and broader cardiometabolic health in T2DM, with potential value in managing complex comorbid profiles. Full article
(This article belongs to the Special Issue Hypertension and Cardiovascular Disease: Clinical Updates and Perspectives)
11 pages, 686 KiB  
Article
Exploring the Impact of Blood Draws on the Intraocular Pressure of Older Adults: A Focus on Physiological Responses
by Aida Ramón-Campillo, Inmaculada Bueno-Gimeno, Javier Gene-Morales, Pablo Jiménez-Martínez, Oscar Caballero-Luna and Andrés Gené-Sampedro
J. Clin. Med. 2024, 13(21), 6554; https://doi.org/10.3390/jcm13216554 - 31 Oct 2024
Viewed by 465
Abstract
Background/Objectives: This study investigated intraocular pressure (IOP) changes after a blood draw in older adults considering sex, age, and baseline IOP. Methods: Fifty-three subjects (54.7% females; age: 68.50 ± 4.46 years; Visual Function Index [VF14]: 94.50 ± 7.50 points; mean contrast [...] Read more.
Background/Objectives: This study investigated intraocular pressure (IOP) changes after a blood draw in older adults considering sex, age, and baseline IOP. Methods: Fifty-three subjects (54.7% females; age: 68.50 ± 4.46 years; Visual Function Index [VF14]: 94.50 ± 7.50 points; mean contrast sensitivity function (CSF) for both eyes in each spatial frequency [cdp]: 1.5 cdp [1.41 ± 0.20 log], 3 cdp [1.57 ± 0.29 log], 6 cdp [1.45 ± 0.39 log], 12 cdp [1.04 ± 0.40 log], 18 cdp [0.63 ± 0.31 log]) voluntarily participated. Subjects fasted for at least 8 h before attending the laboratory. First, IOP was measured in a seated position using a portable rebound tonometer. Ten minutes after the initial measurement, two 10 mL tubes of blood were drawn. Five minutes after the blood draw IOP was measured again following the same procedure as the initial measurement. We evaluated the differences using an analysis of variance. Results: Significant, but not clinically relevant, decreases were found in the right eye, with small effect sizes (p = 0.013–0.079, d = 0.35). Only males and subjects older than 68 years showed trends toward IOP reduction in the right eye. Subjects with baseline IOP ≥ 14 mmHg experienced significant IOP reductions in both eyes, with moderate effect sizes (p = 0.001–0.002, d = 0.56–0.69). Conclusions: Our findings suggest that a blood draw of 20 mL is safe for the IOP levels of older adults with baseline IOP between 11 and 21 mmHg. Variations in IOP were observed based on baseline IOP, sex, and age, suggesting the importance of personalized clinical assessments. The primary factor influencing IOP changes appears to be the baseline IOP level. Full article
(This article belongs to the Special Issue Hypertension and Cardiovascular Disease: Clinical Updates and Perspectives)
►▼ Show Figures

Figure 1

11 pages, 252 KiB  
Article
Validation of the Novel Web-Based Application HUMTELEMED for a Comprehensive Assessment of Cardiovascular Risk Based on the 2021 European Society of Cardiology Guidelines
by Matteo Landolfo, Francesco Spannella, Alessandro Gezzi, Federico Giulietti, Lucia Sabbatini, Isabella Bari, Romina Alessandroni, Angelica Di Agostini, Paolo Turri, Francesco Alborino, Lorenzo Scoppolini Massini and Riccardo Sarzani
J. Clin. Med. 2024, 13(8), 2295; https://doi.org/10.3390/jcm13082295 - 16 Apr 2024
Viewed by 1274
Abstract
Background and aims: SCORE2/SCORE2-OP cardiovascular risk (CVR) charts and online calculators do not apply to patients with comorbidities, target organ damage, or atherosclerotic cardiovascular disease, for whom the assessment relies on the conventional consultation of the 2021 ESC guidelines (qualitative approach). To simplify [...] Read more.
Background and aims: SCORE2/SCORE2-OP cardiovascular risk (CVR) charts and online calculators do not apply to patients with comorbidities, target organ damage, or atherosclerotic cardiovascular disease, for whom the assessment relies on the conventional consultation of the 2021 ESC guidelines (qualitative approach). To simplify the CVR evaluation, we developed an integrated multi-language and free-to-use web application. This study assessed the agreement between the conventional method versus our web app. Methods: A cross-sectional study was carried out on 1306 consecutive patients aged 40+ years referred to our center for the diagnosis and management of hypertension and dyslipidemia. Two double-blind operators performed the CVR assessment and classified each patient into low–moderate-, high-, and very-high-risk categories by using the conventional method (SCORE2/SCORE2-OP charts and consultation of the 2021 ESC guidelines) and the web app. The Kappa statistics were used to compare the two methods. Results: The mean age was 60.3 ± 11.9 years, with male prevalence (51.4%). Patients in primary prevention were 77.0%. According to the SCORE2/SCORE2-OP charts and 2021 ESC guideline consultation, the CVR was low–moderate in 18.6% (n° 243), high in 36.8% (n° 480), and very high in 44.6% (n° 583). According to the web app, individual CVR was low–moderate in 19.5% (n° 255), high in 35.4% (n° 462), and very high in 45.1% (n° 589). The two methods strongly agreed (Kappa = 0.960, p < 0.001), with a 97.5% concordance. Conclusions: our application has excellent reliability in a broad “real life” population and may help non-expert users and busy clinicians to assess individual CVR appropriately, representing a free-to-use, simple, time-sparing and widely available alternative to the conventional CVR evaluation using SCORE2/SCORE2-OP and 2021 ESC guideline charts. Full article
(This article belongs to the Special Issue Hypertension and Cardiovascular Disease: Clinical Updates and Perspectives)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop